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ABSTRACT
Introduction: Efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, was demonstrated in
randomised controlled trials; data on its real-world impact in routine clinical practice are starting to
emerge. We assessed the effectiveness and safety of mepolizumab prescribed for patients in the real world.
Methods: REALITI-A is a global, prospective, observational cohort study, collecting data from routine
healthcare visits from patients with asthma. Patients newly prescribed mepolizumab for severe asthma with
12 months of relevant medical history pre-mepolizumab (collected retrospectively) were enrolled. An
initial analysis of data from early initiators who had completed 1 year of follow-up (as of February 28,
2019) was conducted. The primary objective was to compare the rate of clinically significant exacerbations
(requiring oral corticosteroids (OCS) and/or hospitalisation and/or emergency department visit) before
and after mepolizumab; exacerbations requiring hospitalisation and/or emergency department visit and
change in maintenance OCS use were secondary objectives. Treatment-related adverse events were
reported.
Results: Overall, 368 mepolizumab-treated patients were included. Rates of clinically significant
exacerbations were reduced by 69% from 4.63 per person per year pre-treatment to 1.43 per person per
year during follow-up (p<0.001), as were those requiring hospitalisation and/or emergency department
visit (from 1.14 to 0.27 per person per year; 77% reduction). In 159 patients with maintenance OCS dose
data available during the pre-treatment period, median daily dose decreased from 10.0 (pre-treatment) to
5.0 mg·day−1 by week 21–24 of follow-up, sustained until week 53–56. No new safety signals were
reported.
Conclusion: These data demonstrate that the effectiveness of mepolizumab is consistent with clinical trial
results under real-world settings, with significant reductions in exacerbations and daily maintenance OCS
dose.
This article has supplementary material available from erj.ersjournals.com
Data sharing: Upon completion of the primary analysis, anonymised individual participant data and study documents
can be requested for further research from www.clinicalstudydatarequest.com.
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Introduction
Of the estimated 300 million people worldwide with asthma, 5–10% are expected to experience severe
disease, placing a significant burden on patients and healthcare systems [1–6]. Many patients with severe
asthma receiving maximal inhaled controller medication continue to experience exacerbations [1]. Severe
eosinophilic asthma is one of several phenotypes of severe asthma, and is associated with persistent
eosinophilic inflammation, reduced lung function, poor asthma control and recurrent exacerbations, with/
without systemic corticosteroid (SCS) use [1, 7–11].
Mepolizumab is an anti-interleukin-5 monoclonal antibody that selectively inhibits eosinophilic
inflammation [12]. In clinical trials, add-on mepolizumab therapy, to standard of care, reduced
exacerbations, decreased oral corticosteroid (OCS) dependence, and improved lung function, asthma
control and health-related quality of life versus matched placebo in patients with severe eosinophilic
asthma with a history of exacerbations [13–16]. It is approved as an add-on treatment for patients with
severe eosinophilic asthma [17, 18].
Clinical trial eligibility criteria often result in a more homogenous patient population regarding
demographics and disease characteristics than patients treated in routine clinical practice [8, 19]. Although
clinical trials have high internal validity, they do not replicate real-world conditions [20]. Indeed, a
manifesto by the Respiratory Effectiveness Group stated it is necessary to obtain data on outcomes from
patients treated in the real world for external validity, to complement clinical trials and guide
treatment-related decisions [21]. The 24-month REALITI-A study evaluates mepolizumab use in clinical
practice. Here, we report an initial analysis of data from patients who had completed 12 months of
follow-up by February 28, 2019, following mepolizumab initiation. They represent some of the first to be
prescribed mepolizumab in real-world clinical practice.
Methods
Subjects
Eligible patients were aged ⩾18 years with a current clinical diagnosis of asthma, a physician decision to
initiate mepolizumab treatment and relevant medical records for ⩾12 months pre-enrolment, and who had
provided informed consent for study participation. Prior use of other biological medications was
permitted; those who had received mepolizumab in the year pre-enrolment were excluded. Patients who
had participated in an interventional clinical trial within the year pre-enrolment were also excluded.
Patients were recruited from 51 centres in seven countries (table 1).
Study design
REALITI-A (GSK study identifier 204710) is a global, prospective, single-arm, observational cohort study
enrolling patients diagnosed with asthma and newly prescribed mepolizumab treatment (physician
decision) (figure 1 and supplementary material). The index date was the first mepolizumab administration.
Enrolment could occur before or after the index date; if occurring before the index date, there was a
variable-length run-in period (driven by local prescribing and dispensing practices) between the enrolment
and index dates, where the same therapy was continued. There was no run-in period when the enrolment
and index dates were the same day or when enrolment occurred after the index date (maximum 7 days
permitted from index to enrolment).
The pre-mepolizumab treatment period ended on the index date and started: 1) 365 days pre-enrolment
date if the index date was before the enrolment date; 2) 365 days (+1 day) if the index date and enrolment
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TABLE 1 Demographics and clinical characteristics during the pre-mepolizumab treatment
period (baseline)
Total population 368
Age at enrolment years (n=367)
Mean±SD 53.1±13.7
Median (IQR) 54.0 (44.0–63.0)
Female (n=367) 226 (62)
Race
White/Caucasian 337 (92)











BMI at enrolment kg·m−2
Mean±SD 28.7±7.3
Median (IQR) 27.5 (23.7–32.4)
Smoking history at enrolment (n=364)
Never-smoker 221 (61)
Current smoker 10 (3)
Ex-smoker 133 (37)
Asthma duration at enrolment years (n=360)
Mean±SD 20.0±15.1
Median (IQR) 17.41 (7.00–30.66)
Previous use of omalizumab (n=365) 71 (19)#
Duration of omalizumab treatment months (n=70)
Mean±SD 29.1±31.7
Median (IQR) 14.5 (6.0–48.0)




Daily maintenance OCS dose+ mg·day−1 (n=159)
Mean±SD 14.4±19.5
Median (IQR) 10.0 (5.0–15.0)
Rate of exacerbations per person per year (n=366)
Clinically significant exacerbations
Mean±SD 4.63±4.09
Median (IQR) 3.0 (2.0–6.0)
Exacerbations requiring hospitalisation and/or emergency department visit
Mean±SD 1.14±2.26
Median (IQR) 0 (0.0–1.0)
Exacerbations requiring hospitalisation
Mean±SD 0.60±1.33
Median (IQR) 0 (0.0–1.0)
Blood eosinophil count§ cells·µL−1 (n=357)
Geometric mean±SD logs 370±1.248





Pre-bronchodilator FEV1 L (n=201)
Mean±SD 1.94±0.79
Median (IQR) 1.84 (1.39–2.42)
Pre-bronchodilator FVC L (n=201)
Mean±SD 2.93±1.02
Median (IQR) 2.82 (2.28–3.57)
Continued
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Median (IQR) 0.66 (0.58–0.73)
Pre-bronchodilator FEV1 % pred (n=200)
Mean±SD 64.41±20.34
Median (IQR) 65.65 (47.60–80.33)
Reversibility % (n=39)
Mean±SD 6.97±8.33
Median (IQR) 4.93 (0.90–13.48)
Post-bronchodilator FEV1 L (n=70)
Mean±SD 2.06±0.94
Median (IQR) 2.08 (1.34–2.72)
Post-bronchodilator FVC L (n=70)
Mean±SD 3.07±1.20
Median (IQR) 3.04 (2.10–3.88)
Post-bronchodilator FEV1/FVC (n=70)
Mean±SD 0.66±0.13
Median (IQR) 0.67 (0.58–0.75)
Post-bronchodilator FEV1 % pred (n=70)
Mean±SD 67.22±23.19
Median (IQR) 69.10 (48.09–85.25)
ACQ-5 score§ (n=350)
Mean±SD 3.0±1.4
Median (IQR) 3.2 (2.2–4.0)
Medical history reported during 12 months prior to the enrolment date
Any 343 (93)
Recognised to be associated with asthma
Any asthma related 292 (79)
Hay fever 193 (52)
Chronic sinusitis 145 (39)
Nasal polyps 140 (38)
Any drug hypersensitivity 127 (35)
Nasal polypectomy 96 (26)
Atopic dermatitis 47 (13)
Anaphylaxis 24 (7)
Conditions of interest (reported in ⩾5% of patients)
Any condition of interest 285 (77)











Oropharyngeal candidiasis 33 (9)
Data are presented as n or n (%), unless otherwise stated; percentages may not add up to 100% due to
rounding. IQR: interquartile range; BMI: body mass index; OCS: oral corticosteroid; FEV1: forced expiratory
volume in 1 s; FVC: forced vital capacity; ACQ-5: five-item Asthma Control Questionnaire; COPD: chronic
obstructive pulmonary disease. #: during the enrolment period, 13 out of 71 (18%) patients had received
omalizumab treatment outside of a clinical trial and the remaining 58 out of 71 (82%) patients had received
omalizumab treatment >12 months prior to enrolment that may have been within or outside of a clinical
trial (data were collected for 12 months prior to enrolment only); in those patients who received
omalizumab in the prior 12 months, typically, the end of omalizumab treatment was ∼1–2 months prior to
starting mepolizumab. ¶: reported by the patient. +: during the period including the index date and the
27 days prior to index or any other 27-day period in the last 6 months if no records existed 27 days
immediately prior to index. §: latest record prior to index. ƒ: pneumonia cases were limited to the prior
12 months.
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date were the same or 3) 365 days (+run-in period+1 day) if the enrolment date was pre-index date. Data
were collected retrospectively at enrolment (and, if relevant, prospectively during the run-in period) from
medical records and patient recall for the previous year.
The 12-month follow-up period after initiating mepolizumab was from the index date (+1 day) to the first
of: death, withdrawal of consent or end of follow-up. The present analysis was conducted in the first
cohort of participants in the study who, on February 28, 2019, had completed 12 months of follow-up
after starting mepolizumab. Data were collected prospectively at asthma healthcare visits (routine or
unscheduled) during the 12-month post-index period; no visits were scheduled specifically for this
observational study. The study population subset included in this analysis was enrolled from December
2016 to February 2018; full study population enrolment completed on October 31, 2019.
Outcomes
The primary objective was to compare the clinically significant asthma exacerbation rate in the
pre-mepolizumab treatment period versus the 12-month follow-up period. Clinically significant
exacerbations were defined as a deterioration in asthma requiring SCS (any dose; oral steroids (e.g.
prednisone) for ⩾3 days or a single systemic administration of corticosteroids (intravenous/intramuscular
dose)) and/or hospitalisation and/or emergency department visit. For patients already receiving
maintenance SCS, at least double the existing maintenance dose for ⩾3 days was required. Exacerbations
treated with courses of corticosteroids separated by <7 days were classed as the same exacerbation (based
on data entry by physicians).
Secondary objectives compared the following outcomes in the same periods: asthma exacerbation rates
requiring hospitalisation and/or emergency department visit, or hospitalisation only, and proportion of
patients without clinically significant exacerbations, and those achieving >0–<50% and ⩾50–100%
reductions in clinically significant exacerbation rates. Additionally, for patients who reported at enrolment
they were receiving maintenance OCS (supplementary material), the change and percentage reduction in
median daily maintenance OCS dose from pre-treatment to 12 months after initiating mepolizumab were
assessed. The proportion of patients receiving maintenance OCS pre-mepolizumab treatment who
discontinued maintenance OCS with mepolizumab was also reported. Change from baseline in blood
eosinophil count was also assessed. Safety objectives included reported mepolizumab-related adverse events
and serious adverse events. The relationship of adverse events to mepolizumab was determined by the
investigator without further adjudication.
Post-mepolizumab treatment initiation#
Pre-mepolizumab








Data collected prospectively at routine healthcare visits
Initial analysis of data from patients who
had completed 12 months of follow-up
(early treatment initiators) (n=368)+







FIGURE 1 Study design. #: there will be a 12-month interim analysis of the full study population (primary and
secondary objectives) and a 24-month analysis of the full study population (secondary objectives). ¶: if
enrolment occurred before the index date, there was a variable-length run-in period where patients continued
with the same therapy; there was no run-in period when the enrolment and index dates were the same day or
when the index date occurred before enrolment. +: data cut-off 28 February 2019.
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Analysis
With the assumption that 25% of patients would withdraw during the full study period (supplementary
material), a 12-month mepolizumab treatment period with 200 patients was expected to have 90% power
to detect a 35% reduction in clinically significant exacerbations at the two-sided 5% level. The treated
population, used for all effectiveness and safety evaluations, included all enrolled patients who received one
mepolizumab dose or more. Subgroup analyses were performed by blood eosinophil count (<150, ⩾150–
<300 and ⩾300 cells·µL−1) at index or the most recent count available pre-index. Additional post hoc
subgroup analyses for clinically significant exacerbations were performed by maintenance OCS use and
dose in the pre-treatment period (yes versus no; <10 versus ⩾10 mg·day−1), age at enrolment (<65 versus
⩾65 years of age) and prior omalizumab use during lifetime (yes versus no), and for blood eosinophil
count by maintenance OCS use and dose in the pre-treatment period.
A treatment policy estimand approach for treatment discontinuation was used in this study, which
provided an estimate of the expected effect of mepolizumab using all data collected during the 12-month
follow-up period, regardless of whether patients discontinued mepolizumab. This analysis corresponds to
an intent-to-treat analysis in a clinical trial.
The exacerbation rate in the pre-treatment and 12-month follow-up periods was analysed using negative
binomial regression with time period (pre-treatment and 12-month follow-up) as a covariate. The mean
estimate variance was corrected for within-patient correlation by use of generalised estimating equations
(GEEs). The proportion of patients without clinically significant exacerbations was analysed using logistic
regression and pre-treatment versus post-treatment initiation period data were compared via GEEs with
time period as a covariate. Proportions of patients with ⩾50% reduction in clinically significant
exacerbation rates are also reported. The mean OCS dose was calculated for each patient over each 28-day
period during pre-treatment and the 12-month follow-up. For the mean calculation, a 0 mg dose was
assumed if no data were recorded for a specific day (supplementary material); if a recorded dose could not
be interpreted, the mean was based on the number of days with interpretable data. Summary statistics
(including median) of the OCS maintenance dose were based on the mean value calculated as described
earlier. Patient-specific percentage change from baseline in maintenance OCS daily dose was calculated at
each post-treatment time-point. Applying the distribution-free method [22] to this variable, the median
percent reduction (with 95% confidence interval) from baseline was estimated at 12 months post-treatment
initiation (i.e. week 53–56). The ratio to baseline for blood eosinophil count was assessed using mixed
model repeated measures. Only data on mepolizumab-related adverse events or other GSK products were
collected during the study.
This study was conducted in accordance with the Declaration of Helsinki. Local ethical approval was
obtained per study site.
Results
Patients
Overall, 368 patients received one mepolizumab dose or more in the treated population. The UK enrolled
the most patients (n=136) in this analysis (table 1). The mean body mass index at enrolment was
28.7 kg·m−2, 39% (143 out of 364) of patients were current smokers or ex-smokers and 48% (174 out of
365) were receiving maintenance OCS pre-mepolizumab treatment (table 1). Of those with baseline blood
eosinophil count data available, 51 out of 357 (14%) had baseline blood eosinophil counts <150 cells·µL−1,
45 out of 357 (13%) had counts ⩾150–<300 cells·µL−1 and 261 out of 357 (73%) had counts
⩾300 cells·µL−1. When stratified by baseline blood eosinophil count, 32 out of 51 (63%), 32 out of 45
(71%) and 108 out of 258 (42%) patients in the <150, ⩾150–<300 and ⩾300 cells·µL−1 subgroups,
respectively, reported using maintenance OCS in the pre-treatment period. Additionally, 38% (140 out of
368) of patients had a clinical history of nasal polyps.
At data cut-off, patients had received a mean±SD of 11.4±3.11 mepolizumab treatments, with a mean±SD
treatment duration of 340.4±87.24 days. Overall, 70 out of 368 (19%) patients discontinued mepolizumab
during the 12-month follow-up; the most common reason was participant decision (27 out of 368 (7%)),
while 13 out of 368 (4%) patients reported lack of efficacy (supplementary table S1).
Exacerbations
The clinically significant exacerbation rate fell from 4.63 per person per year in the pre-mepolizumab
treatment period to 1.43 per person per year in the 12-month follow-up, equating to a significant 69%
reduction (rate ratio 0.31 (95% CI 0.27–0.35); p<0.001) (figure 2). Exacerbation rate reductions were
similar across baseline blood eosinophil count subgroups (figure 2).
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The exacerbation rate requiring hospitalisation and/or emergency department visit was also significantly
reduced by 77% from 1.14 per person per year pre-treatment to 0.27 per person per year during follow-up
(rate ratio 0.23 (95% CI 0.18–0.30); p<0.001); reductions were observed across all baseline blood eosinophil
count subgroups (figure 2). Additionally, there was a significant reduction (p<0.001) in the exacerbation
rate requiring hospitalisation in the overall population following treatment, with a similar trend observed
across all baseline blood eosinophil count subgroups.
Overall, 67% (247 out of 366) of patients achieved a ⩾50% reduction in clinically significant exacerbations
from pre-treatment to 12 months after mepolizumab initiation; this rose to 73% (247 out of 340) when
those without a prior history of exacerbations pre-treatment were excluded (table 2). Furthermore, a
significantly higher proportion of patients had no clinically significant exacerbations during follow-up
(48%) versus pre-treatment (7%; OR 12.13 (95% CI 8.03–18.33); p<0.001) (figure 3). Across baseline blood
eosinophil count subgroups, the proportion of patients without clinically significant exacerbations during
follow-up rose to 38–49% versus 7–9% during pre-treatment (figure 3). Clinically significant exacerbations
assessed by maintenance OCS use and dose in the pre-treatment period, age at enrolment, and prior
omalizumab use are shown in supplementary figure S1.
Maintenance OCS
Data on maintenance OCS dose during pre-treatment were available for 159 patients (supplementary
material). The median (interquartile range (IQR)) daily maintenance OCS dose fell from 10.0 (5.0–
15.0) mg·day−1 during pre-treatment to 5.0 (0.9–10.0) mg·day−1 by week 21–24 and remained at the same
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FIGURE 2 Asthma exacerbation rates in the pre-mepolizumab treatment period (365 days prior to enrolment plus any exacerbations starting
during run-in) and 12-month follow-up period. BEC: blood eosinophil count. The n-value indicates the number of patients.
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(95% CI 50.0–75.0%) (i.e. week 53–56) (figure 4a). Of the 125 patients on maintenance OCS at week 53–
56 with data available, 82 remained on OCS at week 53–56, with 34% (43 out of 125) of patients
discontinuing OCS while on mepolizumab (data are from the while-on-treatment estimand for treatment
discontinuation) (figure 5).
In the <150, ⩾150–<300 and ⩾300 cells·µL−1 baseline blood eosinophil count subgroups, the median daily
maintenance OCS dose during pre-treatment was reduced from 12.8, 11.3 and 9.8 to 6.5, 5.0 and
2.5 mg·day−1, respectively, by week 53–56; reductions were seen as early as week 9–12, 13–16 and 5–8,
respectively (figure 4b–d). At week 53–56, median percent reductions from baseline in median daily
maintenance OCS dose in the <150, ⩾150–<300 and ⩾300 cells·µL−1 baseline blood eosinophil count
subgroups were 51% (95% CI 22–74%), 23% (95% CI 0–69%) and 74% (95% CI 50–100%), respectively.
Blood eosinophil count
Following mepolizumab treatment initiation, blood eosinophil count was reduced from least squares
geometric mean 370 (95% CI 320–410) cells·µL−1 at baseline to 60 (95% CI 50–80) cells·µL−1 at month
TABLE 2 Patients achieving a reduction# in the rate of clinically significant exacerbations
during the 12-month follow-up period
Total
population¶
Population with one exacerbation or more
in the pre-mepolizumab treatment period+
Subjects 368 340
⩾50–100% reduction 247 (67) 247 (73)
>0–<50% reduction 52 (14) 52 (15)
No change/increase 66 (18) 40 (12)
Missing§ 1 (<1) 1 (<1)
Data are presented as n or n (%). #: based on 365 days prior to enrolment plus any exacerbations starting
during run-in; ¶: denominator based on patients with data for historical exacerbations only (n=366);
+: denominator based on patients with one historical exacerbation or more only (n=340); patients with zero
historical exacerbations were excluded (n=26); §: one patient did not have data during the follow-up period
and is therefore not included in any of the categories.
0 10 20 40 60 80 10030 50 70 90
49 (n=260)
7 (n=259)
Baseline BEC ≥300 cells·μL–1
38 (n=45)
9 (n=45)
Baseline BEC ≥150–<300 cells·μL–1
43 (n=51)
8 (n=51)









FIGURE 3 Proportion of patients with no clinically significant exacerbations in the pre-mepolizumab treatment
period (365 days prior to enrolment plus any exacerbations starting during run-in) and 12-month follow-up
period. BEC: blood eosinophil count. The n-value indicates the number of patients.
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9–12 (median (IQR) blood eosinophil count values were 442 (270–800) cells·µL−1 at baseline and 90 (40–
100) cells·µL−1 at month 9–12). This corresponds to a reduction of 83% to 60 cells·µL−1 (least squares
mean ratio to baseline at month 9–12: 0.17 (95% CI 0.13–0.21)). The reduction in blood eosinophil count
was observed by month 0–3 and was maintained throughout the 12-month follow-up. Supplementary
table S2 presents blood eosinophil count by maintenance OCS use and dose in the pre-treatment period.
Safety
Overall, 53 out of 368 (14%) patients experienced an investigator-determined treatment-related adverse
event during follow-up (table 3). The most common adverse events (occurring in ⩾2% of patients) were
disorders classified as affecting the nervous system (predominantly headache), general and administration
site, musculoskeletal and connective tissue, skin and subcutaneous tissue, and gastrointestinal tract.
Treatment-related serious adverse events were experienced by two out of 368 (<1%) patients during
follow-up (table 3). Treatment-related serious adverse events of hypersensitivity and pharyngeal swelling
were experienced by one patient each. During follow-up, nine out of 368 (2%) patients experienced a
treatment-related adverse event, leading to permanent treatment discontinuation (table 3). No
treatment-related deaths occurred.
Discussion
The REALITI-A study is a prospective, global, observational, self-controlled cohort study being conducted
to collect real-world data from patients with asthma who were newly prescribed mepolizumab treatment.
These initial results showed real-world mepolizumab initiation led to significant reductions in the annual
asthma exacerbation rate and clinically meaningful reductions in daily maintenance OCS dose versus
pre-mepolizumab treatment. Furthermore, there were no new safety concerns with mepolizumab when
compared with results from previous randomised controlled trials (RCTs). These initial data confirm
mepolizumab effectiveness in a real-world setting.
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FIGURE 4 Maintenance oral corticosteroid (OCS) use after initiation with mepolizumab treatment for a) the overall population and according to the
following baseline (BL) blood eosinophil count subgroups: b) <150, c) ⩾150–<300 and d) ⩾300 cells·µL−1. The median percentage change was
calculated using the distribution-free method [22] with patient-specific percentage change from BL as a variable. The n-value indicates the
number of patients.
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We found the rates of clinically significant exacerbations and exacerbations requiring hospitalisation and/or
emergency department visit were significantly reduced with mepolizumab treatment initiation versus before
initiation. Reductions in clinically significant exacerbations were observed regardless of older age, maintenance
OCS at enrolment or prior use of omalizumab. The treatment policy estimand included data from patients
who discontinued mepolizumab, providing a conservative effectiveness estimate. Our results support those
from the clinical trials MENSA (ClinicalTrials.gov identifier NCT01691521) and MUSCA (ClinicalTrials.gov
identifier NCT02281318), where patients receiving mepolizumab (subcutaneous dose) experienced respective
53% and 58% reductions in the rate of clinically significant exacerbations versus placebo, despite the placebo
effect observed in both studies [14, 15]. Additionally, our data are also consistent with findings from several
smaller, observational studies of real-world mepolizumab treatment for severe asthma [23–27].
TABLE 3 Treatment-related adverse events and serious adverse events
Total population 368
Patients with adverse events 53 (14)
Adverse events occurring most frequently (⩾2% of patients)
Nervous system disorders 26 (7)
General disorders and administration site conditions 12 (3)
Musculoskeletal and connective tissue disorders 9 (2)
Skin and subcutaneous tissue disorders 9 (2)
Gastrointestinal disorders 6 (2)
Patients with adverse events leading to treatment discontinuation# 9 (2)
Patients with adverse events leading to study withdrawal 7 (2)
Serious adverse events 2 (<1)
Hypersensitivity 1 (<1)
Pharyngeal swelling 1 (<1)
Fatal serious adverse events 0 (0)
Data are presented as n or n (%). #: the adverse events leading to treatment discontinuation included
headache (n=2 (<1%)), dizziness (n=1 (<1%)), paraesthesia (n=1 (<1%)), dyspepsia (n=1 (<1%)), nausea (n=1
(<1%)), palpitations (n=1 (<1%)), tachycardia (n=1 (<1%)), vertigo (n=1 (<1%)), noncardiac chest pain (n=1
(<1%)), hypersensitivity (n=1 (<1%)), arthralgia (n=1 (<1%)), pharyngeal swelling (n=1 (<1%)) and pruritus





































































































FIGURE 5 Proportion of patients on maintenance oral corticosteroid (OCS) at enrolment who continued with
maintenance OCS after treatment initiation with mepolizumab. BL: baseline. Data are from the
while-on-treatment estimand for treatment discontinuation (i.e. data considered up to treatment
discontinuation). The n-value indicates the number of patients receiving OCS (together with the number of
patients with OCS data).
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Daily maintenance OCS use was also assessed. We observed a clinically meaningful reduction in the
median daily maintenance OCS dose during follow-up in patients who were on maintenance OCS
pre-mepolizumab treatment. Reductions were also meaningful when assessed by baseline blood eosinophil
count, although the smaller sample sizes resulted in larger variability. Approximately one-third of patients
discontinued maintenance OCS by week 53–56. Similar to our results, a 50% reduction in the median
OCS dose in patients receiving mepolizumab versus placebo was demonstrated in the SIRIUS trial
(ClinicalTrials.gov identifier NCT01691508) and has also been reported in smaller real-world
observational studies [13, 23–27]. These reductions are particularly important in patients with severe
asthma given the risk of adverse events associated with chronic SCS use, irrespective of dose level, and the
additional healthcare costs related to corticosteroid-induced adverse events in patients with severe asthma
[28, 29]. Thus, this large international, prospective REALITI-A study, together with the findings from
these smaller observational studies, provides evidence that the clinical benefits observed with mepolizumab
in clinical trials translate to the real-world setting and indicates that mepolizumab may help reduce the
severe asthma healthcare burden.
In contrast to RCTs with selected, homogeneous populations, this real-world study included a
heterogeneous population, with a broader spectrum of comorbidities and concomitant medications versus
those typically permitted in RCTs. Additionally, unlike RCTs, this real-world population was subject to
payer reimbursement criteria, which differed among countries. Data from REALITI-A complement those
from RCTs; however, more importantly, they highlight mepolizumab effectiveness in the context of
real-world clinical practice. The REALITI-A patient population had particularly severe asthma, as
approximately half of the patients received maintenance OCS pre-mepolizumab treatment, and patients
had an average of 1.2 exacerbations requiring hospitalisation and/or emergency department visit in the
12 months pre-study enrolment. It is perhaps not surprising these early treatment initiators in this analysis
had such severe disease as new treatments are often channelled to those in the most severe spectrum of
the disease [30]. Furthermore, nearly 50% of patients in this initial analysis were from the UK, where
treatment eligibility criteria are particularly more stringent than enrolment criteria applied in clinical trials
and the eligibility criteria in many other REALITI-A countries. However, despite the REALITI-A
population in this analysis being more severe than those patients with severe eosinophilic asthma in the
RCTs [13–16] with no previous smoking history or lung function status restrictions, clinical outcomes are
at least as good as those in the clinical trial setting. Thus, the REALITI-A study provides conformational
validity of the more formal trials and, as such, identifies that the therapeutic benefit of mepolizumab is
translated in the real-world environment.
The relationship between higher blood eosinophil counts and mepolizumab responses in patients with
severe asthma has been identified in previous studies [13–16], with increasing evidence supporting
mepolizumab use in patients with baseline blood eosinophil counts ⩾150 cells·µL−1 [31–33]. This
population is defined by serious morbidity, which increases with higher eosinophil counts (which act as a
predictor of mepolizumab response for exacerbation reduction) [15, 34–38]. In our study, similar
reductions in the clinically significant exacerbation rate and the median daily maintenance OCS use
between pre-treatment and follow-up were seen across all baseline blood eosinophil subgroups, including
the <150 cells·µL−1 subgroup. Although mepolizumab is licensed for the treatment of severe eosinophilic
asthma and usually requires evidence of elevated blood eosinophils [18], the treated severe asthma
population in this real-world setting included 51 (14%) patients with baseline blood eosinophil counts
<150 cells·µL−1 on entry. However, most of these patients had confirmatory evidence of severe eosinophilic
asthma as they had blood eosinophil counts ⩾300 cells·µL−1 during the previous year (and run-in period if
relevant) (67% (34 out of 51)) and/or were requiring maintenance OCS at enrolment (63% (32 out of 51)).
Limitations of real-world studies include the capturing of data from standard clinical care recording;
therefore, there may be missing information. To mitigate this, one study entry criterion was that patients
needed 12 months of relevant medical records available before enrolment; this was done so information on
exacerbation history could be obtained as accurately as possible. Nevertheless, it is possible some historical
exacerbations were overlooked, owing to inadequate recording or self-medication, which would lead to an
underestimation of the impact of mepolizumab. Additionally, as REALITI-A is a real-world study, therapy
could be discontinued or changed by the patient or physician. Patient behaviour may be harder to control
in real-world studies and discontinuation rates in real-world studies have been shown to be higher than
those observed in RCTs, with patient decision and lack of efficacy accounting for most treatment
withdrawals [39]. In this 1-year study, 19% of patients discontinued treatment, which is similar to the rate
observed in other real-world studies [39]. Some of these individuals may not have had a positive response
to mepolizumab and discontinued from the study. It is feasible that some patients had severe eosinophilic
asthma alongside other diseases, and any continued symptoms in these patients may have been due to
nonasthma disease and incorrectly interpreted as a lack of response to mepolizumab. However, only 4%
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discontinued mepolizumab because of lack of efficacy, so this is unlikely to be a significant confounding
factor. Patients may also have withdrawn owing to failure to meet payer reimbursement criteria, an option
that was not listed on the electronic case report form. Furthermore, the treatment policy estimand
approach for treatment discontinuation used, whereby all who received one mepolizumab dose or more
were included, attempts to limit any bias owing to study dropouts. As this is an ongoing study and an
interim analysis on a subcohort of patients, changes to the datasets may occur; however, all efforts were
made to finalise the data to the best standard. Finally, REALITI-A is not a placebo-controlled study;
therefore, outcomes may represent a combination of treatment effect and other behavioural changes. While
this is inherent in all real-world open-label studies, this analysis of early initiators in the real world shows
that the effects of mepolizumab are consistent with those demonstrated in the severe asthma clinical trials
and identifies the clinical benefits of mepolizumab are translated in the severe asthma population in the
real world.
In conclusion, data from this initial analysis of mepolizumab treatment initiation in patients with asthma
treated in routine clinical practice demonstrated mepolizumab was associated with significant reductions in
asthma exacerbations and clinically significant reductions in maintenance OCS use. Additionally,
mepolizumab was well tolerated with a safety profile that appeared to be similar to previous clinical studies
conducted in patients with severe eosinophilic asthma [14–16]. These data also show the mepolizumab
efficacy found in clinical trials translates to the real world and provide valuable insights into treatment
outcomes in patients treated in this setting.
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